PMID- 36703794
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230408
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Expert guidance on prophylaxis and treatment of dermatologic adverse events with 
      Tumor Treating Fields (TTFields) therapy in the thoracic region.
PG  - 975473
LID - 10.3389/fonc.2022.975473 [doi]
LID - 975473
AB  - Tumor Treating Fields (TTFields) are electric fields, delivered via wearable 
      arrays placed on or near the tumor site, that exert physical forces to disrupt 
      cellular processes critical for cancer cell viability and tumor progression. As a 
      first-in-class treatment, TTFields therapy is approved for use in newly diagnosed 
      glioblastoma, recurrent glioblastoma, and pleural mesothelioma. Additionally, 
      TTFields therapy is being investigated in non-small cell lung cancer (NSCLC), 
      brain metastases from NSCLC, pancreatic cancer, ovarian cancer, hepatocellular 
      carcinoma, and gastric adenocarcinoma. Because TTFields therapy is well tolerated 
      and delivery is locoregional, there is low risk of additive systemic adverse 
      events (AEs) when used with other cancer treatment modalities. The most common AE 
      associated with TTFields therapy is mild-to-moderate skin events, which can be 
      treated with topical agents and may be managed without significant treatment 
      interruptions. Currently, there are no guidelines for oncologists regarding the 
      management of TTFields therapy-related skin AEs in the thoracic region, 
      applicable for patients with pleural mesothelioma or NSCLC. This publication aims 
      to provide guidance on preventing, minimizing, and managing dermatologic AEs in 
      the thoracic region to help improve patient quality of life and reduce treatment 
      interruptions that may impact outcomes with TTFields therapy.
CI  - Copyright (c) 2023 Anadkat, Lacouture, Friedman, Horne, Jung, Kaffenberger, 
      Kalmadi, Ovington, Kotecha, Abdullah and Grosso.
FAU - Anadkat, Milan J
AU  - Anadkat MJ
AD  - Division of Dermatology, Department of Medicine, Washington University, St. 
      Louis, MO, United States.
FAU - Lacouture, Mario
AU  - Lacouture M
AD  - Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer 
      Center, New York, NY, United States.
FAU - Friedman, Adam
AU  - Friedman A
AD  - Division of Dermatology, Department of Medicine, George Washington University 
      School of Medicine and Health Sciences, Washington, DC, United States.
FAU - Horne, Zachary D
AU  - Horne ZD
AD  - Department of Radiation Oncology, Allegheny Health Network Cancer Institute, 
      Pittsburgh, PA, United States.
FAU - Jung, Jae
AU  - Jung J
AD  - Department of Dermatology, Norton Healthcare, Louisville, KY, United States.
FAU - Kaffenberger, Benjamin
AU  - Kaffenberger B
AD  - Wexner Medical Center, Ohio State University, Columbus, OH, United States.
FAU - Kalmadi, Sujith
AU  - Kalmadi S
AD  - Oncology and Haematology Department, Ironwood Cancer & Research Center, Chandler, 
      AZ, United States.
FAU - Ovington, Liza
AU  - Ovington L
AD  - Ovington & Associates, Walnutport, PA, United States.
FAU - Kotecha, Rupesh
AU  - Kotecha R
AD  - Miami Cancer Institute, Baptist Health South Florida, Miami, FL, United States.
FAU - Abdullah, Huda Ismail
AU  - Abdullah HI
AD  - Novocure Inc., New York, NY, United States.
FAU - Grosso, Federica
AU  - Grosso F
AD  - Mesothelioma Unit, SS Antonio e Biagio General Hospital, Alessandria, Italy.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20230104
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9873416
OTO - NOTNLM
OT  - TTFields
OT  - Tumor Treating Fields
OT  - skin adverse events
OT  - skin management
OT  - thoracic oncology
COIS- MJA reports personal fees as a past consultant for ImClone, Bristol Myers Squibb, 
      AstraZeneca, Therakos, Aspire Bariatrics, Biogen, Amgen, Veloce, Adgero, Eli 
      Lilly, AbbVie, UCB Biopharma, OnQuality Pharmaceuticals, and Innovaderm Research. 
      MJA is an advisor and/or consultant for Boehringer-Ingelheim, OnQuality 
      Pharmaceuticals, Novocure, Springworks Therapeutics, BioLinq, and Protagonist. ML 
      reports personal fees as a consultant for Johnson & Johnson, Novocure, QED, 
      Bicara Therapeutics, Janssen, Novartis, F. Hoffmann-La Roche AG, EMD Serono, 
      AstraZeneca, Innovaderm Research, Deciphera, DFB Pharmaceuticals, Azitra, Kintara 
      Therapeutics, La Roche-Posay, Trifecta Pharmaceuticals, Varsona Therapeutics, 
      Genentech, Loxo Oncology, Seagen, Lutris Pharma, OnQuality Pharmaceuticals, 
      Oncoderm Labs, NCODA, and Apricity Therapeutics. ML has received funding for 
      research from Lutris Pharma, Paxman, Novocure, Johnson & Johnson, US Biotest, 
      OQL, Novartis, and AstraZeneca. ML has received grant funding from the NIH/NCI 
      Cancer Center Support (Grant P30 CA008748). AF reports personal fees as a 
      consultant for L'Oreal, La Roche-Posay, Galderma, Aveeno, MicroCures, Pfizer, 
      Novartis, Menlo Therapeutics, Incyte, Eli Lilly, MINO Labs, Dermira, Zylo 
      Therapeutics, Hoth Therapeutics, Corbus Pharmaceuticals, FSD pharma, Regeneron, 
      Sanofi, AbbVie, Insed, Brickell Biotech, and UCB. AF has received grant funding 
      from Pfizer, Galderma, and Incyte. AF reports honoraria from Incyte, Janssen, 
      AbbVie, Regeneron, and UCB. ZH reports personal fees as a consultant for 
      Novocure, AstraZeneca, Regeneron, and Sanofi Genzyme. ZH has received honoraria 
      from Novocure. JJ reports honoraria from Regeneron and Sanofi. BHK reports 
      personal fees as a consultant for Novocure, Novartis, and Eli Lilly. BHK is an 
      investigator for Biogen, Janssen, OnQuality Pharmaceuticals, Merck, and InflaRx. 
      SK reports funding for research from Novocure, Bristol Myers Squibb, Novartis, 
      Janssen, and AstraZeneca. SK reports personal fees as a consultant for Janssen, 
      F. Hoffmann-La Roche AG, Novartis, Pfizer, AstraZeneca, and TG therapeutics. LO 
      reports personal fees as a consultant for Ethicon Inc. RK reports personal fees 
      as a consultant for Accuray, Elekta, ViewRay, Novocure, Elsevier, and Brainlab. 
      LO reports institutional research funding from Medtronic, Blue Earth Diagnostics 
      Ltd, Novocure, GT Medical Technologies, AstraZeneca, Exelixis, ViewRay, and 
      Brainlab. HA is an employee of Novocure and holds stocks in Novocure. FG reports 
      personal fees for advisory roles, speaker engagements, and travel and 
      accommodation expenses from Merck, Novocure, Bristol Myers Squibb, Boehringer 
      Ingelheim, PharmaMar, Novartis, and Pierre Fabre. Writing and editorial support 
      provided by Prime was funded by Novocure Inc. and conducted according to Good 
      Publication Practice guidelines (Link).
EDAT- 2023/01/28 06:00
MHDA- 2023/01/28 06:01
PMCR- 2022/01/01
CRDT- 2023/01/27 02:15
PHST- 2022/06/22 00:00 [received]
PHST- 2022/09/23 00:00 [accepted]
PHST- 2023/01/27 02:15 [entrez]
PHST- 2023/01/28 06:00 [pubmed]
PHST- 2023/01/28 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.975473 [doi]
PST - epublish
SO  - Front Oncol. 2023 Jan 4;12:975473. doi: 10.3389/fonc.2022.975473. eCollection 
      2022.